Evaluation of the usefulness of six commercial agglutination assays for serologic diagnosis of toxoplasmosis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      Network from the French National Reference Center for Toxoplasmosis
    • Source:
      Publisher: Elsevier Biomedical Country of Publication: United States NLM ID: 8305899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0070 (Electronic) Linking ISSN: 07328893 NLM ISO Abbreviation: Diagn Microbiol Infect Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: [New York, NY] : Elsevier Biomedical, [c1983-
    • Subject Terms:
      Agglutination Tests/*methods ; Toxoplasmosis/*diagnosis; Antibodies, Protozoan/blood ; Diagnostic Errors/statistics & numerical data ; Humans ; Immunoglobulin G/blood ; Immunoglobulin M/blood ; Sensitivity and Specificity ; Serologic Tests/methods ; Toxoplasma/immunology
    • Abstract:
      Six agglutination tests for detecting Toxoplasma gondii-specific antibodies (immunoglobulin G or M) in serum were performed and compared. In total, 599 sera were examined using direct and indirect agglutination assays. Sensitivity varied from 93.7% to 100% and specificity from 97.1% to 99.2%. In a selected population with interfering diseases, the percentage of false positives ranged from 4.3% to 10.9%. Although an overall agreement of 100% was found for chronic toxoplasmosis, sensitivity for the detection of confirmed acute toxoplasmosis ranged from 86.4% to 97.3%. Regarding the large variability in terms of the performance of the 6 assays, tests based on the hemagglutination principle were found to be better than the other agglutination tests for all the panels evaluated, meaning that they could be used as qualitative or semiquantitative low-cost screening assays.
      (Copyright © 2012 Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Investigator: A Totet; B Cimon; E Scherer; I Accoceberry; G Nevez; D Quinio; J Bonhomme; B Carme; M Demar; A Bonnin; B Cuisenier; F Dalle; N Desbois; MP Brenier-Pinchart; H Fricker-Hidalgo; H Pelloux; L Delhaes; D Ajzenberg; ML Dardé; J Franck; R Piarroux; P Bastien; Y Sterkers; F Pratlong; M Machouart; M Leterrier; F Morio; N Ferret; C Pomares; P Marty; A Angoulvant; S Houze; T Ancelle; H Yera; F Derouin; J Menotti; ME Bougnoux; N Hassouni; F Touafek; L Paris; N Godineau; P Roux; C Hennequin; S Azi; J Berthonneau; D Aubert; C Chemla; I Villena; F Robert-Gangneux; L Favennec; G Gargala; P Flori; E Candolfi; D Filisetti; O Villard; J Filiaux; S Cassaing; N Vanlangendonck
    • Accession Number:
      0 (Antibodies, Protozoan)
      0 (Immunoglobulin G)
      0 (Immunoglobulin M)
    • Publication Date:
      Date Created: 20120501 Date Completed: 20121009 Latest Revision: 20191210
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.diagmicrobio.2012.03.014
    • Accession Number:
      22541791